Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
GNCA Genocea Biosciences
0.001
-0.006-85.71%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Financial Ratios
Efficiency Ratios TTM
Fixed Assets Turnover(T)
44.55% 0.1406 1.83% 0.1185 1.83% 0.1185 2.94% 0.1208
Total Asset Rate(T)
47.95% 0.0311 18.12% 0.0212 18.12% 0.0212 16.78% 0.0192
ROIC
-4.80% -146.595% 24.23% -83.186% 24.23% -83.186% 14.19% -66.249%
ROE
13.64% -525.779% 29.82% -184.131% 29.82% -184.131% 19.66% -120.278%
ROA
8.66% -60.608% 25.71% -42.983% 25.71% -42.983% 11.38% -40.792%
Efficiency Ratios
ROE 5 Year Average
-- -- -1.07% -2101.902% -- -- -- --
ROA 5 Year Average
-- -- 2.55% -87.624% -- -- -- --
Average 5 Years ROIC
-- -- -4.37% -129.024% -- -- -- --
Profitability Ratios TTM
Operating Margin
14.35% -2901.308% 8.19% -3174.467% 8.19% -3174.467% 7.53% -3071.176%
Net Margin
38.27% -1946.154% 37.11% -2022.913% 37.11% -2022.913% 24.11% -2126.813%
EBITDA Margin
38.90% -18.0754% 38.65% -18.5972% 38.65% -18.5972% 25.30% -19.6533%
R & D Expense Ratio
-7.18% 2235.110% -4.85% 2377.820% -4.85% 2377.820% -8.05% 2228.760%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-29.03% 766.200% -15.31% 896.650% -15.31% 896.650% -5.52% 942.410%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-92.31% 67.606% -59.72% 37.666% -- 37.666% -- --
Total Assets to Common Equity
-93.43% 313.185% -81.15% 206.711% -- 206.711% -- --
Debt to Asset Ratio
-88.79% 125.030% -76.12% 63.472% -- 63.472% -- --
Current Ratio
-77.53% 1.3537 -31.95% 2.2385 -- 2.2385 -- --
Quick Ratio
-80.68% 1.1169 -37.70% 1.9883 -- 1.9883 -- --
GrowthRatios
Growth Ratios
Revenue CAGR(5Y)
-- -- 212.66% 47.506% -- -- -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
CEO: Mr. William D. Clark
Market: Pink Market
Listing Date: 02/05/2014
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist